Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH-High, Therapy-Resistant Cancer Cells

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Kim, Sang Kyum ^a,b   Kim, Honsoul ^b   Lee, Da hye ^a   Kim, Tae shin ^a   Kim, Tackhoon ^a   Chung, Chaeuk ^a   Koh, Gou Young ^a   Kim, Hoguen ^b   Lim, Dae Sik ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; DISULFIRAM; GEMCITABINE; DEOXYCYTIDINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL SUBPOPULATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PREOPERATIVE TREATMENT; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THERAPY RESISTANCE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, PANCREATIC DUCTAL; DRUG DELIVERY SYSTEM; DRUG RESISTANCE; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREATIC NEOPLASMS; PHYSIOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ALDEHYDE DEHYDROGENASE; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DISULFIRAM; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84886070383     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078130     Document Type: Article

References (49)

1. Saif MW, (2011) Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January. JOP (2011): 12: 106-109.
2. Hidalgo M, (2010) Pancreatic cancer. N Engl J Med 362: 1605-1617. doi:10.1056/NEJMra0901557. PubMed: 20427809.
3. Dean M, Fojo T, Bates S, (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284. doi:10.1038/nrc1590. PubMed: 15803154.
4. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323. doi:10.1016/j.stem.2007.06.002. PubMed: 18371365.
5. Wicha MS, Liu S, Dontu G, (2006) Cancer stem cells: an old idea--a paradigm shift. Cancer Res 66: 1883-1895; discussion: 16488983.
6. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, et al. (2009) A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 8: 310-314. doi:10.1158/1535-7163.MCT-08-0924. PubMed: 19174553.
7. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, et al. (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350: 1200-1210. doi:10.1056/NEJMoa032295. PubMed: 15028824.
8. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, et al. (2007) Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 246: 734-740. doi:10.1097/SLA.0b013e318156eef3. PubMed: 17968163.
9. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, et al. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685-1695. doi:10.1002/cncr.10831. PubMed: 12365016.
10. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230: 774-782; discussion: 10615932.
11. Bakkevold KE, Arnesjø B, Dahl O, Kambestad B, (1993) Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A: 698-703. PubMed: 8471327.
12. Rasheed ZA, Yang J, Wang Q, Kowalski J, Freed I, et al. (2010) Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 102: 340-351. doi:10.1093/jnci/djp535. PubMed: 20164446.
13. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, et al. (2011) Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLOS ONE 6: e16530. doi:10.1371/journal.pone.0016530. PubMed: 21304978.
14. Dorado J, Serrano AG, Heeschen C, (2011) Cancer Stem Cells in Solid Organs; Allan AL, eds. London: Springer Verlag Science+Business Media.
15. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, et al. (2007) ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 1: 555-567. doi:10.1016/j.stem.2007.08.014. PubMed: 18371393.
16. Li T, Su Y, Mei Y, Leng Q, Leng B, et al. (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest 90: 234-244. doi:10.1038/labinvest.2009.127. PubMed: 20010854.
17. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, et al. (2009) Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis. Cancer Res 69: 3382-3389. doi:10.1158/0008-5472.CAN-08-4418. PubMed: 19336570.
18. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, et al. (2009) Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338. doi:10.1158/1541-7786.MCR-08-0393. PubMed: 19276181.
19. Johansson B, (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 369: 15-26. PubMed: 1471547.
20. Chen D, Cui QC, Yang H, Dou QP, (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66: 10425-10433. doi:10.1158/0008-5472.CAN-06-2126. PubMed: 17079463.
21. Wang W, McLeod HL, Cassidy J, (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104: 504-511. doi:10.1002/ijc.10972. PubMed: 12584750.
22. Brar SS, Grigg C, Wilson KS, Holder WD Jr., Dreau D, et al. (2004) Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther 3: 1049-1060. PubMed: 15367699.
23. Wang F, Zhai S, Liu X, Li L, Wu S, et al. (2011) A novel dithiocarbamate analogue with potentially decreased ALDH inhibition has copper-dependent proteasome-inhibitory and apoptosis-inducing activity in human breast cancer cells. Cancer Lett 300: 87-95. doi:10.1016/j.canlet.2010.09.010. PubMed: 21035945.
24. Sauna ZE, Peng XH, Nandigama K, Tekle S, Ambudkar SV, (2004) The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 65: 675-684. doi:10.1124/mol.65.3.675. PubMed: 14978246.
25. Cvek B, Dvorak Z, (2007) Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals. Curr Pharm Des 13: 3155-3167. doi:10.2174/138161207782110390. PubMed: 17979756.
26. Cho HJ, Lee TS, Park JB, Park KK, Choe JY, et al. (2007) Disulfiram suppresses invasive ability of osteosarcoma cells via the inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol 40: 1069-1076. doi:10.5483/BMBRep.2007.40.6.1069. PubMed: 18047805.
27. Dalla Pozza E, Donadelli M, Costanzo C, Zaniboni T, Dando I, et al. (2011) Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives. Free Radic Biol Med 50: 926-933. doi:10.1016/j.freeradbiomed.2011.01.001. PubMed: 21236335.
28. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. (2010) AJCC cancer staging manual. New York: Springer Verlag.
29. Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, et al. (1999) Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17: 2208-2212. PubMed: 10561277.
30. Eneanya DI, Bianchine JR, Duran DO, Andresen BD, (1981) The actions of metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 21: 575-596. doi:10.1146/annurev.pa.21.040181.003043. PubMed: 7016017.
31. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661. PubMed: 17942826.
32. Strobel O, Dor Y, Alsina J, Stirman A, Lauwers G, et al. (2007) In vivo lineage tracing defines the role of acinar-to-ductal transdifferentiation in inflammatory ductal metaplasia. Gastroenterology 133: 1999-2009. doi:10.1053/j.gastro.2007.09.009. PubMed: 18054571.
33. Nagasao J, Yoshioka K, Amasaki H, Mutoh K, (2003) Centroacinar and intercalated duct cells as potential precursors of pancreatic endocrine cells in rats treated with streptozotocin. Ann Anat 185: 211-216. doi:10.1016/S0940-9602(03)80025-0. PubMed: 12801084.
34. Gasslander T, Ihse I, Smeds S, (1992) The importance of the centroacinar region in cerulein-induced mouse pancreatic growth. Scand J Gastroenterol 27: 564-570. doi:10.3109/00365529209000120. PubMed: 1641582.
35. Rovira M, Scott SG, Liss AS, Jensen J, Thayer SP, et al. (2010) Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas. Proc Natl Acad Sci U S A 107: 75-80. doi:10.1073/pnas.0912589107. PubMed: 20018761.
36. Balber AE, (2011) Concise Review: Aldehyde Dehydrogenase Bright Stem and Progenitor Cell Populations from Normal Tissues: Characteristics, Activities, and Emerging Uses in Regenerative Medicine. Stem Cells 29: 570-575. doi:10.1002/stem.613. PubMed: 21308868.
37. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, et al. (2011) ALDH Activity Selectively Defines an Enhanced Tumor-Initiating Cell Population Relative to CD133 Expression in Human Pancreatic Adenocarcinoma. PLOS ONE 6: e20636. doi:10.1371/journal.pone.0020636. PubMed: 21695188.
38. Yao J, Cai HH, Wei JS, An Y, Ji ZL, et al. (2010) Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells. Oncol Rep 23: 1375-1382. PubMed: 20372854.
39. Mishra G, Butler J, Ho C, Melin S, Case LD, et al. (2005) Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28: 345-350. doi:10.1097/01.coc.0000159559.42311.c5. PubMed: 16062075.
40. Magnino A, Gatti M, Massucco P, Sperti E, Faggiuolo R, et al. (2005) Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. Oncology 68: 493-499. doi:10.1159/000086993. PubMed: 16020980.
41. Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, et al. (2010) Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial. Int J Radiat Oncol Biol Phys 77: 1426-1432. doi:10.1016/j.ijrobp.2009.06.053. PubMed: 20056351.
42. Gordon MY, Goldman JM, (1985) Gordon-Smith. Ecologist 4-Hydroperoxycyclophosphamide inhibits proliferation by human granulocyte-macrophage colony-forming cells (GM-CFC) but spares more primitive progenitor cells. Leuk Res 9: 1017-1021.
43. Sahovic EA, Colvin M, Hilton J, Ogawa M, (1988) Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res 48: 1223-1226. PubMed: 3342403.
44. Moreb JS, Turner C, Sreerama L, Zucali JR, Sladek NE, et al. (1995) Interleukin-1 and tumor necrosis factor alpha induce class 1 aldehyde dehydrogenase mRNA and protein in bone marrow cells. Leuk Lymphoma 20: 77-84. doi:10.3109/10428199509054756. PubMed: 8750626.
45. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, et al. (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLOS ONE 3: e2428. doi:10.1371/journal.pone.0002428. PubMed: 18560594.
46. Maeda S, Shinchi H, Kurahara H, Mataki Y, Noma H, et al. (2007) Clinical significance of midkine expression in pancreatic head carcinoma. Br J Cancer 97: 405-411. doi:10.1038/sj.bjc.6603879. PubMed: 17622248.
47. Singh B, Murphy RF, Ding XZ, Roginsky AB, Bell RH Jr., et al. (2007) On the role of transforming growth factor-beta in the growth inhibitory effects of retinoic acid in human pancreatic cancer cells. Mol Cancer 6: 82. doi:10.1186/1476-4598-6-82. PubMed: 18157915.
48. Rainey JM Jr., (1977) Disulfiram toxicity and carbon disulfide poisoning. Am J Psychiatry 134: 371-378. PubMed: 190907.
49. Fuller RK, Gordis E, (2004) Does disulfiram have a role in alcoholism treatment today? Addiction 99: 21-24. doi:10.1111/j.1360-0443.2004.00597.x. PubMed: 14678055.